Multispecific NK engager proteins

Patent metadata

Field	Value
Publication number	US-10113003-B2
Application number	US-201615190337-A
Country	US
Kind code	B2
Filing date	Jun 23, 2016
Priority date	Jun 23, 2015
Publication date	Oct 30, 2018
Grant date	Oct 30, 2018

Abstract

Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

First claim

The invention claimed is:

1. A method of promoting the specific lysis of cancer cells expressing an antigen of interest which is specifically bound by a therapeutic anti-cancer antibody or therapeutic anti-cancer antigen-binding antibody fragment in a subject in need thereof comprising contacting said cancer cells with an amount of a multispecific antigen binding protein sufficient to promote the specific lysis of said cancer cells expressing said antigen of interest, wherein said multispecific antigen binding protein comprises:
(i) a first antigen binding domain (ABD) which monovalently binds to a human NKp46 polypeptide having the amino acid sequence set forth in SEQ ID NO:1,
(ii) a second ABD which comprises a therapeutic anti-cancer antibody or a therapeutic anti-cancer antigen-binding antibody fragment which binds to said antigen of interest-expressed by said cancer cells, and
(iii) a CD16A binding polypeptide,

wherein:
(1) said NKp46-binding ABD comprises a Fab or comprises a variable heavy (V H ) domain and a variable light (V L ) domain separated by a linker (“scFv”);
(2) said cancer-antigen-binding ABD, which comprises said therapeutic anti-cancer antibody or therapeutic anti-cancer antigen-binding antibody fragment, is monovalent or bivalent;
(3) said CD16A binding polypeptide comprises a dimeric human Fc domain polypeptide which binds CD16A;
(4) said multispecific antigen binding protein binds to the NKp46 polypeptide monovalently;
(5) said multispecific antigen binding protein directs NKp46-expressing natural killer (NK) cells and CD16A-expressing NK cells to lyse cancer cells expressing the cancer antigen of interest by a combination of NKp46-mediated signaling and CD16A-mediated antibody-dependent cell-mediated cytotoxicity (“ADCC”);
(6) said dimeric Fc domain interposes said first ABD and said second ABD;
(7) said first and second ABD are each connected to said dimeric Fc domain, and one or both of said first and second ABD are connected to the dimeric Fc domain via a flexible polypeptide linker.

2. The method of claim 1 , wherein the cancer-antigen-binding ABD comprises a Fab or comprises a V H domain and a V L domain separated by a linker comprising a linear or cyclic peptide.

3. The method of claim 1 , wherein the NKp46-binding ABD comprises a Fab.

4. The method of claim 1 , wherein the NKp46-binding ABD comprises a V H domain and a V L domain separated by a linker comprising a linear or cyclic peptide.

5. The method of claim 1 wherein said dimeric Fc polypeptide of (3) comprises a modification that enhances CD16A binding relative to the corresponding wild-type Fc region.

6. The method of claim 1 , wherein the administration of said multispecific antigen binding protein increases the expression of CD137 on the surface of NK cells in said subject.

7. The method of claim 1 , wherein the NKp46-binding ABD is comprised of a V H domain and a V L domain, wherein each of the V H and V L domains are positioned within a tandem variable region comprising a V H domain and a V L domain separated by a polypeptide linker.

8. The method of claim 1 , wherein the NKp46-binding ABD is a Fab comprised of a V H domain and a V L domain, wherein each of the V H and V L domains is fused to a human C H1 or C κ constant domain.

9. The method of claim 8 , wherein the NKp46-binding ABD is a Fab comprised of (a) a V H domain fused to a human C H1 constant domain and a V L domain fused to a human C κ constant domain, or (b) a V H domain fused to a human C κ constant domain and a V L domain fused to a human C H1 constant domain.

10. The method of claim 1 , wherein the cancer-antigen-binding ABD is a Fab comprised of a V H domain and a V L domain, wherein each of the V H and V L domains is fused to a human C H1 or C κ constant domain.

11. The method of claim 10 , wherein the cancer-antigen-binding ABD is a Fab comprised of (a) a V H domain fused to a human C H1 constant domain and a V L domain fused to a human C κ constant domain, or (b) a V H domain fused to a human C κ constant domain and a V L domain fused to a human C H1 constant domain.

12. The method of claim 1 , wherein either or both the NKp46-binding ABD or the cancer-antigen-binding ABD is bound to the Fc domain by a flexible polypeptide linker.

13. The method of claim 1 , wherein the monovalent NKp46 ABD comprises V H and V L domain polypeptides selected from the group consisting of:
(a) the V H and V L domains of SEQ ID NOS: 3 and 4 (NKp46-1);
(b) the V H and V L domains of SEQ ID NOS: 5 and 6 (NKp46-2);
(c) the V H and V L domains of SEQ ID NOS: 7 and 8 (NKp46-3);
(d) the V H and V L domains of SEQ ID NOS: 9 and 10 (NKp46-4);
(e) the V H and V L domains of SEQ ID NOS: 11 and 12 (NKp46-6); and
(f) the V H and V L domains of SEQ ID NOS: 13 and 14 (NKp46-9).

14. The method of claim 1 , wherein said combination of NKp46-mediated signaling and CD16A-mediated ADCC has an additive or synergistic effect on the lysis of cancer cells expressing the antigen of interest.

15. A method of promoting the specific lysis of hematological cancer cells expressing an antigen of interest which is specifically bound by a therapeutic anti-cancer antibody or therapeutic anti-cancer antigen-binding antibody fragment in a subject in need thereof, comprising contacting said hematological cancer cells with an amount of a multispecific antigen binding protein which is sufficient to promote the specific lysis of said hematological cancer cells expressing said therapeutic cancer antigen, wherein said multispecific antigen binding protein comprises:
(i) a first antigen binding domain (ABD) which monovalently binds to a human NKp46 polypeptide having the amino acid sequence set forth in SEQ ID NO:1,
(ii) a second ABD which comprises a therapeutic anti-cancer antibody or a therapeutic anti-cancer antigen-binding antibody fragment which binds to said antigen of interest expressed by said hematological cancer cells, and
(iii) a CD16A binding polypeptide,

wherein:
(1) said NKp46-binding ABD comprises a Fab or comprises a V H chain domain and a V L chain domain separated by a linker (“scFv”);
(2) (2) said cancer-antigen-binding ABD, which comprises said therapeutic anti-cancer antibody or therapeutic anti-cancer antigen-binding antibody fragment, is monovalent or bivalent;
(3) said CD16A binding polypeptide comprises a dimeric human Fc domain polypeptide which binds CD16A;
(4) said multispecific antigen binding protein binds to the NKp46 polypeptide monovalently;
(5) said multispecific antigen binding protein directs NKp46-expressing NK cells and CD16A-expressing NK cells to lyse hematological cancer cells expressing the cancer antigen of interest by a combination of NKp46-mediated signaling and CD16A-mediated ADCC;
(6) said dimeric Fc domain interposes said first ABD and said second ABD;
(7) said first and second ABD are each attached to said dimeric Fc domain, and one or both of said first and second ABD are connected to the Fc domain via a flexible polypeptide linker.

16. The method of claim 15 , wherein said combination of NKp46-mediated signaling and CD16A-mediated ADCC has an additive or synergistic effect on the lysis of hematological cancer cells expressing the antigen of interest.

17. The method of claim 15 , wherein the antigen of interest expressed by said hematological cancer cells comprises CD19 or CD20.

18. A method of promoting the specific lysis of cancer cells expressing an antigen of interest which is specifically bound by a therap

Assignees

• Innate Pharma

Inventors

• Gauthier Laurent
• Anceriz Nadia
• Morel Ariane
• Rossi Benjamin

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2317/522

  CH1 domain · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title